These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11320392)

  • 21. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
    Tacket CO; Pasetti MF; Sztein MB; Livio S; Levine MM
    J Infect Dis; 2004 Aug; 190(3):565-70. PubMed ID: 15243933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Madagascar should introduce typhoid conjugate vaccines now.
    Marks F; Kim JH; Rakotozandrindrainy R
    Lancet; 2018 Oct; 392(10155):1309-1310. PubMed ID: 30322578
    [No Abstract]   [Full Text] [Related]  

  • 23. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
    An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
    Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines.
    Thiem VD; Lin FY; Canh DG; Son NH; Anh DD; Mao ND; Chu C; Hunt SW; Robbins JB; Schneerson R; Szu SC
    Clin Vaccine Immunol; 2011 May; 18(5):730-5. PubMed ID: 21411598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.
    Kossaczka Z; Lin FY; Ho VA; Thuy NT; Van Bay P; Thanh TC; Khiem HB; Trach DD; Karpas A; Hunt S; Bryla DA; Schneerson R; Robbins JB; Szu SC
    Infect Immun; 1999 Nov; 67(11):5806-10. PubMed ID: 10531232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG.
    Rijpkema S; Hockley J; Logan A; Rigsby P; Atkinson E; Jin C; Goldblatt D; Liang H; Bachtiar NS; Yang JS; Goel A; Ramasamy V; Pasetti MF; Pollard AJ;
    Biologicals; 2018 Nov; 56():29-38. PubMed ID: 30201529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial.
    Sirima SB; Ouedraogo A; Barry N; Siribie M; Tiono A; Nébié I; Konaté A; Berges GD; Diarra A; Ouedraogo M; Bougouma EC; Soulama I; Hema A; Datta S; Liang Y; Rotrosen ET; Tracy JK; Jamka LP; Oshinsky JJ; Pasetti MF; Neuzil KM; Laurens MB
    Int J Infect Dis; 2021 Jul; 108():465-472. PubMed ID: 34082090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis.
    Welch PG; Fattom A; Moore J; Schneerson R; Shiloach J; Bryla DA; Li X; Robbins JB
    J Am Soc Nephrol; 1996 Feb; 7(2):247-53. PubMed ID: 8785394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.
    Sur D; Ochiai RL; Bhattacharya SK; Ganguly NK; Ali M; Manna B; Dutta S; Donner A; Kanungo S; Park JK; Puri MK; Kim DR; Dutta D; Bhaduri B; Acosta CJ; Clemens JD
    N Engl J Med; 2009 Jul; 361(4):335-44. PubMed ID: 19625715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
    Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
    Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines.
    Gibani MM
    Lancet Infect Dis; 2022 Apr; 22(4):435-436. PubMed ID: 34942089
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccine.
    Szu SC; Lin KF; Hunt S; Chu C; Thinh ND
    Vaccine; 2014 May; 32(22):2618-22. PubMed ID: 24657719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Japanese study to assess immunogenicity and safety of a typhoid Vi polysaccharide vaccine.
    Miyazu M; Kikuchi H; Hamada A; Fukushima S; Ouchi K; Bosch Castells V; Mihara H; Bonnet MC
    Vaccine; 2015 Nov; 33(48):6697-702. PubMed ID: 26518404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV).
    Voysey M; Pollard AJ
    Clin Infect Dis; 2018 Jun; 67(1):18-24. PubMed ID: 29351594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Vi polysaccharide vaccine against strains of Salmonella typhi: reply.
    Keddy KH; Klugman KP; Robbins JB
    Vaccine; 1998; 16(9-10):871-2. PubMed ID: 9682329
    [No Abstract]   [Full Text] [Related]  

  • 36. Typhoid vaccines.
    Aggarwal A; Dutta AK
    Indian J Pediatr; 2001 Aug; 68(8):733-6. PubMed ID: 11563251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan.
    Khan MI; Soofi SB; Ochiai RL; Habib MA; Sahito SM; Nizami SQ; Acosta CJ; Clemens JD; Bhutta ZA;
    Vaccine; 2012 Aug; 30(36):5389-95. PubMed ID: 22721899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component.
    Wetter M; Kowarik M; Steffen M; Carranza P; Corradin G; Wacker M
    Glycoconj J; 2013 Jul; 30(5):511-22. PubMed ID: 23053636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Field effectiveness of Vi polysaccharide typhoid vaccine in the People's Republic of China.
    Arya SC
    J Infect Dis; 2002 Mar; 185(6):845; author reply 845-6. PubMed ID: 11920305
    [No Abstract]   [Full Text] [Related]  

  • 40. Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance.
    Andrews JR; Baker S; Marks F; Alsan M; Garrett D; Gellin BG; Saha SK; Qamar FN; Yousafzai MT; Bogoch II; Antillon M; Pitzer VE; Kim JH; John J; Gauld J; Mogasale V; Ryan ET; Luby SP; Lo NC
    Lancet Infect Dis; 2019 Jan; 19(1):e26-e30. PubMed ID: 30170987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.